Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Chronic Heart Failure

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 267 articles: HTML format

Single Articles

November 2025
1. PETRIE MC, Docherty KF, McMurray JJ
   What Is Heart Failure With Preserved Ejection Fraction?
   J Am Coll Cardiol. 2025;86:1950-1952.
   PubMed    
   
   
   
2. HALL ME, Spruiell CA, Mace HP, Hall JE, et al
   Adiposity and Heart Failure Risk: Time To Stop the "Obesity Paradox" Talk.
   J Am Coll Cardiol. 2025;86:1778-1780.
   PubMed    
   
   
   October 2025
3. MENTZ RJ, Oladuja K
   Adipokine Signaling in Heart Failure With Preserved Ejection Fraction: A New Clinical Frontier.
   J Am Coll Cardiol. 2025;86:1266-1268.
   PubMed    
   
   
   
4. VEST AR, Ilonze OJ, Umapathi P, Harrington J, et al
   Body Composition and Treatment Response in Heart Failure With Preserved Ejection Fraction: Interpreting the Adipokine Hypothesis.
   J Am Coll Cardiol. 2025;86:1256-1259.
   PubMed    
   
   
   
5. BORLAUG BA
   Do Heart Failure With Preserved Ejection Fraction Treatments Work by Targeting Adipose Biology?
   J Am Coll Cardiol. 2025;86:1236-1239.
   PubMed    
   
   
   
6. PACKER M, Testani J, Butler J, Zannad F, et al
   Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.
   J Am Coll Cardiol. 2025 Oct 15:S0735-1097(25)07698.
   PubMed     Abstract available
   
   
   
7. NAKADE T, Fujimoto Y, Singh YS, Akama Y, et al
   Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.
   J Am Coll Cardiol. 2025 Oct 15:S0735-1097(25)09511.
   PubMed     Abstract available
   
   
   
8. RICCARDI M, Pabon MA, Vardeny O, Vaduganathan M, et al
   Reply: Heart Failure With Improved EF: A Transitional State Demanding Targeted Strategies?
   J Am Coll Cardiol. 2025;86:e135-e136.
   PubMed    
   
   
   
9. LUO Y, Ghossein MA, Caliskan K
   Pharmacotherapy for Patients With Heart Failure and Improved Ejection Fraction: Updating Our Understanding.
   J Am Coll Cardiol. 2025;86:e131-e132.
   PubMed    
   
   
   
10. SUN P
    Metabolic Health Status: A Critical Unaddressed Dimension in Obesity Phenotyping for Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Oct 14:S0735-1097(25)07773.
    PubMed    
    
    
    
11. BORLAUG BA, Zile MR, Kramer CM, Packer M, et al
    Reply: Metabolic Health Status: A Critical Unaddressed Dimension in Obesity Phenotyping for Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Oct 14:S0735-1097(25)07772.
    PubMed    
    
    
    
12. NASER JA, Harada T, Tada A, Wong MCK, et al
    Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Oct 13:S0735-1097(25)07766.
    PubMed     Abstract available
    
    
    
13. BUTT JH, Doi SN, Thune JJ, Nielsen JC, et al
    Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.
    J Am Coll Cardiol. 2025 Oct 11:S0735-1097(25)07765.
    PubMed     Abstract available
    
    
    
14. LEE H, Huang X, Khan SS, Son D, et al
    Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease.
    J Am Coll Cardiol. 2025;86:1017-1029.
    PubMed     Abstract available
    
    
    
15. PACKER M, Butler J, Lam CSP, Zannad F, et al
    Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?
    J Am Coll Cardiol. 2025 Oct 1:S0735-1097(25)07501.
    PubMed     Abstract available
    
    
    September 2025
16. CORDERO A, de la Espriella R, Nunez J
    Heart Failure Biomarkers for Atrial Fibrillation Prediction: Why Not CA125?
    J Am Coll Cardiol. 2025;86:e103-e104.
    PubMed    
    
    
    
17. KHAN SS, Damrauer SM
    Personalizing the Paradigm for Heart Failure Prevention.
    J Am Coll Cardiol. 2025;86:874-876.
    PubMed    
    
    
    
18. PACKER M, Lam CSP, Butler J, Zannad F, et al
    Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
    J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07341.
    PubMed     Abstract available
    
    
    
19. BLUMER V, Lindenfeld J, Lala A, Carson P, et al
    Let Us Call It Cardiogenic Preshock: A Working Definition From the Heart Failure Collaboratory.
    J Am Coll Cardiol. 2025;86:832-835.
    PubMed    
    
    
    
20. RICCARDI M, Pagnesi M, Lombardi CM, Anker SD, et al
    Moderate Secondary Mitral Regurgitation: Evolving Evidence and Management Strategies.
    J Am Coll Cardiol. 2025;86:813-828.
    PubMed     Abstract available
    
    
    
21. KITAI T, Kanaoka K, Shoji S, Tsugawa Y, et al
    Heart Failure in the Oldest-Old: A Growing Clinical and Economic Burden in Aging Japan.
    J Am Coll Cardiol. 2025;86:757-760.
    PubMed    
    
    
    
22. LEE AY, Palaniappan L, Rana JS, Lombardo D, et al
    Time to Disaggregate "Asian American" to Address Disparities in Heart Failure Risk.
    J Am Coll Cardiol. 2025;86:735-737.
    PubMed    
    
    
    
23. AMBROSY AP, Daida YG, Parikh RV, Tan TC, et al
    Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.
    J Am Coll Cardiol. 2025;86:725-734.
    PubMed     Abstract available
    
    
    
24. GANGAVELLI A, Steinberg RS, Johnson AE, Ogunniyi MO, et al
    Advancing Equity in Heart Failure Outcomes: From Social Context to Structural Solutions.
    J Am Coll Cardiol. 2025;86:721-724.
    PubMed    
    
    
    
25. HUANG X, Hughes Z, Fonarow GC, Ahmad FS, et al
    Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.
    J Am Coll Cardiol. 2025;86:711-720.
    PubMed     Abstract available
    
    
    
26. SAVARESE G, Butler J
    Incretin-Based Therapies and Heart Failure Outcomes: Benefit Beyond Weight Loss?
    J Am Coll Cardiol. 2025;86:708-710.
    PubMed    
    
    
    
27. PACKER M, Zile MR, Kramer CM, DiMaria JM, et al
    Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
    J Am Coll Cardiol. 2025;86:696-707.
    PubMed     Abstract available
    
    
    August 2025
28. CAI A, Liu L, Feng Y, Li L, et al
    Comparison of Fixed vs Age-Adjusted NT-proBNP Cutoffs to Define Pre-Heart Failure.
    J Am Coll Cardiol. 2025;86:625-629.
    PubMed    
    
    
    
29. KAUL S
    Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
    J Am Coll Cardiol. 2025;86:610-624.
    PubMed     Abstract available
    
    
    
30. VAN ESSEN BJ, Ceelen DCH, Ouwerkerk W, Teng TK, et al
    Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
    J Am Coll Cardiol. 2025 Aug 26:S0735-1097(25)07572.
    PubMed     Abstract available
    
    
    
31. SKAARUP KG, Lassen MCH, Johansen ND, Christensen SH, et al
    Effect of RSV Vaccine on Heart Failure Hospitalizations: A Prespecified Analysis of the DAN-RSV Trial.
    J Am Coll Cardiol. 2025 Aug 26:S0735-1097(25)07467.
    PubMed    
    
    
    
32. OSTROMINSKI JW, Hojbjerg Lassen MC, Butt JH, Claggett BL, et al
    Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials.
    J Am Coll Cardiol. 2025 Aug 23:S0735-1097(25)07398.
    PubMed     Abstract available
    
    
    
33. ZANNAD F, Reddy YNV, Barash I, Anstrom KJ, et al
    Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR.
    J Am Coll Cardiol. 2025 Aug 21:S0735-1097(25)07559.
    PubMed     Abstract available
    
    
    
34. GALLONE G, Baldetti L, Veen KM, Bernhardt AM, et al
    Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis.
    J Am Coll Cardiol. 2025 Aug 21:S0735-1097(25)07381.
    PubMed     Abstract available
    
    
    
35. HALLER PM, Melloni GEM, Berg DD, Kamanu FK, et al
    A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07028.
    PubMed     Abstract available
    
    
    
36. OSTROMINSKI JW, Neuen BL, Claggett BL, Anand IS, et al
    Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07493.
    PubMed     Abstract available
    
    
    
37. PACKER M
    The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07049.
    PubMed     Abstract available
    
    
    
38. WALLACE N, Wong K, Desmarais T, Park JJ, et al
    Optimizing the Primary Prevention of Sudden Cardiac Death in Patients With Heart Failure.
    J Am Coll Cardiol. 2025;86:374-395.
    PubMed     Abstract available
    
    
    
39. FIORETTI F, Testani JM, Tio MC, Pitt B, et al
    Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases.
    J Am Coll Cardiol. 2025;86:354-373.
    PubMed     Abstract available
    
    
    
40. MIN KH, Go AS, Lee K, Parikh RV, et al
    Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction.
    J Am Coll Cardiol. 2025;86:338-350.
    PubMed     Abstract available
    
    
    
41. VADUGANATHAN M, Neuen BL
    Combining SGLT2i and MRAs in Heart Failure: Playing the Long Game.
    J Am Coll Cardiol. 2025;86:334-337.
    PubMed    
    
    
    
42. FERREIRA JP, Vasques-Novoa F, Saraiva F, Oliveira AC, et al
    Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial.
    J Am Coll Cardiol. 2025;86:320-333.
    PubMed     Abstract available
    
    
    
43. KRUMHOLZ HM
    Heart Failure in Practice: What and How.
    J Am Coll Cardiol. 2025;86:317-319.
    PubMed    
    
    
    July 2025
44. BALDETTI L, Ajello S, Gramegna M, Den Uil CA, et al
    Intra-Aortic Balloon Pump in Heart Failure-Related Cardiogenic Shock: Dead or Alive?
    J Am Coll Cardiol. 2025;86:e45-e46.
    PubMed    
    
    
    
45. JOYNT MADDOX KE, Aguilar P
    Private Equity in Heart Failure Care: Where Chronic Disease and Acute Financial Pressures Collide.
    J Am Coll Cardiol. 2025;86:268-270.
    PubMed    
    
    
    
46. BORLAUG BA, Zile MR, Kramer CM, Ye W, et al
    Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.
    J Am Coll Cardiol. 2025;86:242-255.
    PubMed     Abstract available
    
    
    
47. KRAMER CM, Borlaug BA, Zile MR, Packer M, et al
    Reply: Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.
    J Am Coll Cardiol. 2025;85:e219-e220.
    PubMed    
    
    
    
48. FAUCHIER L, Lochon L, Lenormand T
    Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.
    J Am Coll Cardiol. 2025;85:e217.
    PubMed    
    
    
    
49. HAO H, Xu K, Zhang D, Deng Y, et al
    Long-Term Wildfire Smoke Exposure and Increased Risk of Heart Failure in Older Adults.
    J Am Coll Cardiol. 2025;85:2439-2451.
    PubMed     Abstract available
    
    
    June 2025
50. RICCARDI M, Pabon MA, Bhatt AS, Savarese G, et al
    Heart Failure With Improved Ejection Fraction: Definitions, Epidemiology, and Management.
    J Am Coll Cardiol. 2025;85:2401-2415.
    PubMed     Abstract available
    
    
    
51. COTTER G, Davison BA, Bhatt DL
    Less Heart Failure But No Improvement in Quality of Life in FINEARTS-HF: Why the Disconnect?
    J Am Coll Cardiol. 2025;85:2333-2336.
    PubMed    
    
    
    
52. HAZEWINKEL AD, Gregson J, Pocock SJ, McMurray J, et al
    Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical Improvements.
    J Am Coll Cardiol. 2025;85:2304-2323.
    PubMed     Abstract available
    
    
    
53. ARNOLD SV
    Kansas City Cardiomyopathy Questionnaire: A Measure of Heart-Failure Risk, But Can it Improve Outcomes?
    J Am Coll Cardiol. 2025;85:2267-2269.
    PubMed    
    
    
    
54. EL-SABAWI BR, Al-Garadi MA, Steitz BD, Perkins AM, et al
    Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12.
    J Am Coll Cardiol. 2025;85:2253-2266.
    PubMed     Abstract available
    
    
    
55. KITTLESON MM, Benjamin EJ, Blumer V, Harrington J, et al
    2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.
    J Am Coll Cardiol. 2025 Jun 10:S0735-1097(25)06481.
    PubMed     Abstract available
    
    
    
56. JOHNSON DY, Liu M, Bartlett VL, Zheng Z, et al
    Heart Failure Care and Outcomes After Private Equity Acquisition of U.S. Hospitals.
    J Am Coll Cardiol. 2025 Jun 3:S0735-1097(25)06619.
    PubMed     Abstract available
    
    
    May 2025
57. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
    Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025;85:1774-1788.
    PubMed     Abstract available
    
    
    
58. DOCHERTY KF
    SGLT2 Inhibitors in Heart Failure: Iron Mobilization at the Heart of the Matter.
    J Am Coll Cardiol. 2025;85:1771-1773.
    PubMed    
    
    
    
59. FERREIRA JP, Anker SD, Butler J, Filippatos G, et al
    Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program.
    J Am Coll Cardiol. 2025;85:1757-1770.
    PubMed     Abstract available
    
    
    
60. PABON MA, Filippatos G, Claggett BL, Miao MZ, et al
    Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis.
    J Am Coll Cardiol. 2025;85:1649-1660.
    PubMed     Abstract available
    
    
    April 2025
61. EDOARDO G, Arduini A, Iacoviello M, Carugo S, et al
    Albuminuria Range as a Key Metric Linking Renal Function to Heart Failure Outcome in FINEARTS-HF.
    J Am Coll Cardiol. 2025 Apr 14:S0735-1097(25)05906.
    PubMed    
    
    
    
62. CLAUDEL SE, Schmidt IM, Waikar SS, Verma A, et al
    Albuminuria: A Marker of Adverse Kidney Outcomes in Heart Failure.
    J Am Coll Cardiol. 2025;85:1372-1375.
    PubMed    
    
    
    March 2025
63. PACKER M, Zile MR, Kramer CM, Murakami M, et al
    Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
    J Am Coll Cardiol. 2025 Mar 24:S0735-1097(25)05340.
    PubMed     Abstract available
    
    
    
64. MORICI N, Sacco A, Frea S, Rota M, et al
    Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial.
    J Am Coll Cardiol. 2025 Mar 21:S0735-1097(25)05334.
    PubMed     Abstract available
    
    
    
65. PITT B, Budden J, Anker SD, Butler J, et al
    Reply: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs.
    J Am Coll Cardiol. 2025;85:e115.
    PubMed    
    
    
    
66. TANG WZ, Cai QY, Pan YR, Liu TH, et al
    The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs.
    J Am Coll Cardiol. 2025;85:e113.
    PubMed    
    
    
    
67. PACKER M
    Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths.
    J Am Coll Cardiol. 2025;85:985-987.
    PubMed    
    
    
    
68. MAURER MS, Witteles RM, Garcia-Pavia P, Sheikh FH, et al
    Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy.
    J Am Coll Cardiol. 2025 Mar 11:S0735-1097(25)05823.
    PubMed     Abstract available
    
    
    February 2025
69. LALA A, Coca S, Feinman J, Hamo CE, et al
    Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure: JACC Expert Panel From the HF-ARC.
    J Am Coll Cardiol. 2025;85:766-781.
    PubMed     Abstract available
    
    
    
70. KRUMHOLZ HM
    Heart Failure: Insights From a JACC Special Focus Issue.
    J Am Coll Cardiol. 2025;85:683-684.
    PubMed    
    
    
    
71. MOGHTADERI A, Magid DJ, Yuan AY, Black B, et al
    The Association of Hospital-Cardiologist Integration With Patient Outcomes, Care Quality, and Utilization.
    J Am Coll Cardiol. 2025;85:352-361.
    PubMed     Abstract available
    
    
    January 2025
72. MASI S, Dalpiaz H, Savarese G
    Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Jan 22:S0735-1097(24)10659.
    PubMed    
    
    
    
73. BUTLER J, Usman MS, Harrell FE Jr, Packer M, et al
    Did Finerenone Improve Health Status in the FINEARTS Trial?: A Critical Reevaluation of the Analysis of Patient-Reported Outcomes in Heart Failure.
    J Am Coll Cardiol. 2025;85:190-195.
    PubMed     Abstract available
    
    
    
74. DAMMAN K
    When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure.
    J Am Coll Cardiol. 2025;85:186-189.
    PubMed    
    
    
    
75. MATSUMOTO S, Jhund PS, Henderson AD, Bauersachs J, et al
    Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
    J Am Coll Cardiol. 2025;85:173-185.
    PubMed     Abstract available
    
    
    
76. KAUL S, Hiremath S
    Unentangling Heart Failure From Kidney Outcomes With Finerenone: Insights From the FINEARTS-HF Trial.
    J Am Coll Cardiol. 2025;85:169-172.
    PubMed    
    
    
    
77. CHENG RK, Leedy D, Ruberg FL
    Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis?
    J Am Coll Cardiol. 2025 Jan 16:S0735-1097(24)10558.
    PubMed    
    
    
    
78. CLELAND JGF
    Prostanoids and Heart Failure: Friend or Foe?
    J Am Coll Cardiol. 2025;85:71-73.
    PubMed    
    
    
    
79. RADE JJ, Kronsberg SS, Kickler TS, Vasan RS, et al
    Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure.
    J Am Coll Cardiol. 2025;85:58-70.
    PubMed     Abstract available
    
    
    December 2024
80. LOWE EF, Gerasta D, Balser M, Page RL 2nd, et al
    Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications.
    J Am Coll Cardiol. 2024 Dec 17:S0735-1097(24)10426.
    PubMed     Abstract available
    
    
    
81. FONTANA M, Maurer MS, Gillmore JD, Bender S, et al
    Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.
    J Am Coll Cardiol. 2024 Dec 16:S0735-1097(24)10297.
    PubMed     Abstract available
    
    
    
82. VEST AR, Sauer AJ
    Obesity-Related Heart Failure With Preserved Ejection Fraction: Weighing the Benefit of Finerenone.
    J Am Coll Cardiol. 2024 Dec 6:S0735-1097(24)10542.
    PubMed    
    
    
    
83. BUTT JH, Henderson AD, Jhund PS, Claggett BL, et al
    Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.
    J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10423.
    PubMed     Abstract available
    
    
    
84. O'GARA PT
    Transcatheter Aortic Valve Replacement in Heart Failure, Reduced Ejection Fraction, and Moderate Aortic Stenosis.
    J Am Coll Cardiol. 2024 Dec 3:S0735-1097(24)10429.
    PubMed    
    
    
    November 2024
85. COBURN J, Neef PA, Hobson S, Dalzell JR, et al
    Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure.
    J Am Coll Cardiol. 2024;84:e323.
    PubMed    
    
    
    
86. KONDO T, Henderson AD, Docherty KF, Jhund PS, et al
    Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
    J Am Coll Cardiol. 2024;84:2233-2240.
    PubMed     Abstract available
    
    
    
87. KOSIBOROD MN, Cherney DZI, Desai AS, Testani JM, et al
    Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure.
    J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10430.
    PubMed     Abstract available
    
    
    
88. LU H, Kondo T, Claggett BL, Vaduganathan M, et al
    Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials.
    J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10420.
    PubMed     Abstract available
    
    
    
89. FONTANA M, Maurer MS, Gillmore JD, Bender S, et al
    Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial.
    J Am Coll Cardiol. 2024 Nov 9:S0735-1097(24)10464.
    PubMed     Abstract available
    
    
    
90. KRAMER CM, Borlaug BA, Zile M MR, Ruff D, et al
    Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
    J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10414.
    PubMed     Abstract available
    
    
    October 2024
91. NEUEN BL, Badve SV, Arnott C
    Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron.
    J Am Coll Cardiol. 2024;84:1718-1720.
    PubMed    
    
    
    
92. CLELAND JGF, Pellicori P, Graham FJ, Lane R, et al
    Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure.
    J Am Coll Cardiol. 2024;84:1704-1717.
    PubMed     Abstract available
    
    
    
93. DRONKERS J, van Veldhuisen DJ, van der Meer P, Meems LMG, et al
    Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue.
    J Am Coll Cardiol. 2024;84:1666-1677.
    PubMed     Abstract available
    
    
    
94. VAN MIEGHEM NM, Elmariah S, Spitzer E, Pibarot P, et al
    Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD.
    J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)09960.
    PubMed     Abstract available
    
    
    
95. MC CAUSLAND FR, Vaduganathan M, Claggett BL, Kulac IJ, et al
    Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial.
    J Am Coll Cardiol. 2024 Oct 22:S0735-1097(24)10252.
    PubMed     Abstract available
    
    
    
96. GENEREUX P, Gupta A, Makkar RR
    TAVR in Patients with Moderate Aortic Stenosis and Heart Failure.
    J Am Coll Cardiol. 2024 Oct 21:S0735-1097(24)10056.
    PubMed    
    
    
    
97. LANDSTEINER I, Ramesh A, Yang BQ, Lewis GD, et al
    Hemodynamic Insights From Provocative Testing in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2024 Oct 16:S0735-1097(24)09806.
    PubMed    
    
    
    
98. AIMO A, Panichella G, Vergaro G, Bayes-Genis A, et al
    Bridging Atrial and Ventricular Failure Through Biomarkers.
    J Am Coll Cardiol. 2024;84:1541-1544.
    PubMed    
    
    
    
99. TALHA KM, Butler J, Packer M
    Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction.
    J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08453.
    PubMed     Abstract available
    
    
    
100. REDDY YNV, Frantz RP, Hassoun PM, Hemnes AR, et al
     Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension.
     J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08392.
     PubMed     Abstract available
     
     
     
101. ROSMAN L, Lampert R, Wang K, Gehi AK, et al
     Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators.
     J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08455.
     PubMed     Abstract available
     
     
     
102. VARGA CR, Cleland JGF, Abraham WT, Lip GYH, et al
     Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2024;84:1342-1362.
     PubMed     Abstract available
     
     
     
103. GREENE SJ, Spahillari A, Shahzeb Khan M
     Enabling Medical Therapy for Heart Failure: New Tools Bring a New Reality for Hyperkalemia.
     J Am Coll Cardiol. 2024;84:1309-1312.
     PubMed    
     
     
     
104. PITT B, Anker SD, Lund LH, Coats AJS, et al
     Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.
     J Am Coll Cardiol. 2024;84:1295-1308.
     PubMed     Abstract available
     
     
     September 2024
105. LINDBERG F, Savarese G
     Worsening Heart Failure: An Opportunity for Treatment Implementation Even With a Preserved Ejection Fraction?
     J Am Coll Cardiol. 2024 Sep 29:S0735-1097(24)08531.
     PubMed    
     
     
     
106. YANG M, Henderson AD, Talebi A, Atherton JJ, et al
     Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
     J Am Coll Cardiol. 2024 Sep 29:S0735-1097(24)08532.
     PubMed     Abstract available
     
     
     
107. VADUGANATHAN M, Claggett BL, Desai AS, Jhund PS, et al
     Time to Significant Benefit of Finerenone in Patients With Heart Failure.
     J Am Coll Cardiol. 2024 Sep 26:S0735-1097(24)08512.
     PubMed    
     
     
     
108. DESAI AS, Vaduganathan M, Claggett BL, Kulac IJ, et al
     Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.
     J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452.
     PubMed     Abstract available
     
     
     
109. MATSUMOTO S, Shen L, Henderson AD, Bohm M, et al
     Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.
     J Am Coll Cardiol. 2024 Sep 21:S0735-1097(24)08162.
     PubMed     Abstract available
     
     
     
110. MENTZ RJ, Kittipibul V
     Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle.
     J Am Coll Cardiol. 2024;84:1089-1091.
     PubMed    
     
     
     
111. BHATT AS, Bhatt DL, Steg PG, Szarek M, et al
     Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
     J Am Coll Cardiol. 2024;84:1078-1088.
     PubMed     Abstract available
     
     
     
112. NEVES JS, Zannad F, Butler J, Packer M, et al
     Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?
     J Am Coll Cardiol. 2024;84:1119-1122.
     PubMed    
     
     
     
113. MURAKAMI T
     Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle.
     J Am Coll Cardiol. 2024;84:e87.
     PubMed    
     
     
     August 2024
114. PONIKOWSKI P, Friede T, von Bardeleben RS, Butler J, et al
     Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.
     J Am Coll Cardiol. 2024 Aug 30:S0735-1097(24)08233.
     PubMed     Abstract available
     
     
     
115. ANKER MS, Porthun J, Schulze PC, Rassaf T, et al
     Percutaneous Transcatheter Edge-To-Edge Repair for Functional Mitral Regurgitation in Heart Failure: A Meta-Analysis of 3 Randomized Controlled Trials.
     J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08231.
     PubMed    
     
     
     
116. SOLOMON SD, Ostrominski JW, Wang X, Shah SJ, et al
     Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.
     J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08192.
     PubMed     Abstract available
     
     
     
117. VERMA S, Butler J, Borlaug BA, Davies MJ, et al
     Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
     J Am Coll Cardiol. 2024 Aug 29:S0735-1097(24)08195.
     PubMed     Abstract available
     
     
     
118. MODIN D, Claggett B, Johansen ND, Solomon SD, et al
     Excess mortality and hospitalizations associated with seasonal influenza in patients with heart failure.
     J Am Coll Cardiol. 2024 Aug 28:S0735-1097(24)08311.
     PubMed     Abstract available
     
     
     
119. VERMA S, Petrie MC, Borlaug BA, Butler J, et al
     Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
     J Am Coll Cardiol. 2024 Aug 28:S0735-1097(24)08234.
     PubMed     Abstract available
     
     
     
120. MEWTON N, Zores F, Packer M
     Catheter Ablation for Atrial Fibrillation in Advanced Heart Failure: Can We Trust the CASTLE-HTx Trial?
     J Am Coll Cardiol. 2024;84:862-864.
     PubMed    
     
     
     
121. HAHN RT, Lindenfeld J, Lim SD, Mack MJ, et al
     Structural Cardiac Interventions in Patients With Heart Failure: JACC Scientific Statement.
     J Am Coll Cardiol. 2024;84:832-847.
     PubMed     Abstract available
     
     
     
122. OSTROMINSKI JW, Lala A
     Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care.
     J Am Coll Cardiol. 2024;84:786-789.
     PubMed    
     
     
     
123. VADUGANATHAN M, Neuen BL, McCausland F, Jhund PS, et al
     Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure?
     J Am Coll Cardiol. 2024 Aug 27:S0735-1097(24)08242.
     PubMed    
     
     
     
124. KITTIPIBUL V, Mentz RJ
     Effects of GLP-1 Receptor Agonists on Heart Failure Outcomes: The FLOW of Evidence.
     J Am Coll Cardiol. 2024 Aug 24:S0735-1097(24)08168.
     PubMed    
     
     
     
125. PRATLEY RE, Tuttle KR, Rossing P, Rasmussen S, et al
     Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
     J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116.
     PubMed     Abstract available
     
     
     
126. PACKER M, Ferreira JP, Butler J, Filippatos G, et al
     Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.
     J Am Coll Cardiol. 2024 Aug 20:S0735-1097(24)07897.
     PubMed     Abstract available
     
     
     
127. HALLER PM, Jarolim P, Palazzolo MG, Bellavia A, et al
     Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.
     J Am Coll Cardiol. 2024 Aug 19:S0735-1097(24)07965.
     PubMed     Abstract available
     
     
     
128. PATEL RB
     Mechanistic Insights of SGLT2 Inhibition in Heart Failure Through Proteomics: Appreciating the Cardiovascular-Kidney Connection.
     J Am Coll Cardiol. 2024 Aug 12:S0735-1097(24)08016.
     PubMed    
     
     
     
129. OSTROMINSKI JW, Jemma Cho SM, Vaduganathan M, Honigberg MC, et al
     Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes.
     J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747.
     PubMed    
     
     
     
130. KITTLESON MM, Breathett K, Ziaeian B, Aguilar D, et al
     2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures.
     J Am Coll Cardiol. 2024 Aug 5:S0735-1097(24)07288.
     PubMed     Abstract available
     
     
     
131. HOLLENBERG SM, Stevenson LW, Ahmad T, Bozkurt B, et al
     2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee.
     J Am Coll Cardiol. 2024 Aug 2:S0735-1097(24)07449.
     PubMed    
     
     
     July 2024
132. BIEGUS J, Mebazaa A, Davison B, Cotter G, et al
     Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF.
     J Am Coll Cardiol. 2024;84:323-336.
     PubMed     Abstract available
     
     
     
133. LOPEZ J, Liu Y, Butler J, Del Prato S, et al
     Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.
     J Am Coll Cardiol. 2024;84:233-243.
     PubMed     Abstract available
     
     
     
134. HAHN RT, Lindenfeld J, Bohm M, Edelmann F, et al
     Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2024;84:195-212.
     PubMed     Abstract available
     
     
     
135. PETRIE MC, Borlaug BA, Butler J, Davies MJ, et al
     Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
     J Am Coll Cardiol. 2024;84:27-40.
     PubMed     Abstract available
     
     
     
136. VAN KIMMENADE RRJ, Hassing C
     STEP-HFpEF: A Large Step for HFpEF.
     J Am Coll Cardiol. 2024;84:41-42.
     PubMed    
     
     
     June 2024
137. CHEEMA B, Chokshi A, Orimoloye O, Ardehali H, et al
     Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2024;83:2674-2689.
     PubMed     Abstract available
     
     
     
138. VERMA S, Butler J, Borlaug BA, Davies M, et al
     Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
     J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445.
     PubMed     Abstract available
     
     
     
139. SCHOU M, Petrie MC, Borlaug BA, Butler J, et al
     Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
     J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07126.
     PubMed     Abstract available
     
     
     
140. LALA A, Mentz RJ, Santos-Gallego CG
     The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
     J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407.
     PubMed    
     
     
     
141. MESSORI A, Romeo MR, Trippoli S
     Remote Monitoring in Heart Failure: Inclusion of Different Studies in the Same Meta-Analysis.
     J Am Coll Cardiol. 2024;83:e231.
     PubMed    
     
     
     
142. KOCHAR A, Gattani R, Vaduganathan M
     Patient Selection Is the Key to EMPACTing Development of Heart Failure After Myocardial Infarction.
     J Am Coll Cardiol. 2024;83:2247-2249.
     PubMed    
     
     
     
143. CANNATA A, Bromage DI, Piper SE, McDonagh TA, et al
     Heart Failure With Preserved Ejection Fraction: Prioritizing Patients' Symptoms.
     J Am Coll Cardiol. 2024 Jun 11:S0735-1097(24)07300.
     PubMed    
     
     
     May 2024
144. KONDO T, Mogensen UM, Talebi A, Gasparyan SB, et al
     Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
     J Am Coll Cardiol. 2024;83:1973-1986.
     PubMed     Abstract available
     
     
     
145. OSTROMINSKI JW, Claggett BL, Miao ZM, Mc Causland FR, et al
     Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis.
     J Am Coll Cardiol. 2024 May 9:S0735-1097(24)07204.
     PubMed    
     
     
     
146. FERRO CJ, Townend JN
     Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease: Short-Term Pain for Long-Term Gain.
     J Am Coll Cardiol. 2024 May 6:S0735-1097(24)06944.
     PubMed    
     
     
     
147. MATSUMOTO S, Henderson AD, Shen L, Yang M, et al
     Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.
     J Am Coll Cardiol. 2024 May 6:S0735-1097(24)06945.
     PubMed     Abstract available
     
     
     April 2024
148. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
     Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2024;83:1568-1578.
     PubMed     Abstract available
     
     
     
149. BURCHILL LJ, Jain CC, Miranda WR
     Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
     J Am Coll Cardiol. 2024;83:1415-1417.
     PubMed    
     
     
     
150. MARTON A, Saffari SE, Rauh M, Sun RN, et al
     Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
     J Am Coll Cardiol. 2024;83:1386-1398.
     PubMed     Abstract available
     
     
     
151. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
     Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
     J Am Coll Cardiol. 2024;83:1403-1414.
     PubMed     Abstract available
     
     
     
152. ACHANTA A, Belak L, Ritchie CS, Januzzi JL, et al
     Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction.
     J Am Coll Cardiol. 2024;83:1348-1350.
     PubMed    
     
     
     
153. COSTANZO MR, Januzzi JL
     Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
     J Am Coll Cardiol. 2024;83:1307-1309.
     PubMed    
     
     
     
154. COX ZL, Collins SP, Hernandez GA, McRae AT 3rd, et al
     Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.
     J Am Coll Cardiol. 2024;83:1295-1306.
     PubMed     Abstract available
     
     
     
155. COTTER G, Davison B, Chioncel O
     Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2024;83:1243-1252.
     PubMed     Abstract available
     
     
     
156. UDELL JA, Petrie MC, Jones WS, Anker SD, et al
     Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
     J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06757.
     PubMed     Abstract available
     
     
     
157. CHATUR S, Neuen BL, Claggett BL, Beldhuis IE, et al
     Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
     J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06691.
     PubMed     Abstract available
     
     
     
158. MINHAS AMK, Mathew RO, Sperling LS, Nambi V, et al
     Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States.
     J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)00940.
     PubMed    
     
     
     March 2024
159. ATALLAH B, Ghalib HH
     Pooling the NT-proBNP Benefits of ARNI: Fret the Index Hospitalization No More.
     J Am Coll Cardiol. 2024;83:1133-1135.
     PubMed    
     
     
     
160. MORROW DA, Velazquez EJ, Desai AS, DeVore AD, et al
     Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
     J Am Coll Cardiol. 2024;83:1123-1132.
     PubMed     Abstract available
     
     
     
161. GONZALEZ-LOPEZ E, McPhail ED, Salas-Anton C, Dominguez F, et al
     Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2024;83:1085-1099.
     PubMed     Abstract available
     
     
     
162. FOA A, Vaduganathan M, Claggett BL, Pabon MA, et al
     Sacubitril/Valsartan-Related Hypotension in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
     J Am Coll Cardiol. 2024 Mar 13:S0735-1097(24)00478.
     PubMed     Abstract available
     
     
     
163. FUSTER V
     Editor-in-Chief's Top Picks From 2023.
     J Am Coll Cardiol. 2024;83:961-1026.
     PubMed     Abstract available
     
     
     
164. HAGE C, Sundstrom J, Lund LH
     More evidence that heart failure with normal EF distinct from heart failure is below normal EF.
     J Am Coll Cardiol. 2024 Mar 12:S0735-1097(24)00990.
     PubMed    
     
     
     
165. NEWMAN JD, O'Meara E, Bohm M, Savarese G, et al
     Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2024;83:932-950.
     PubMed     Abstract available
     
     
     
166. UDELL JA, Armstrong DWJ
     Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found.
     J Am Coll Cardiol. 2024;83:915-917.
     PubMed    
     
     
     
167. MANN DL, Nicolas J, Claggett B, Miao ZM, et al
     Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.
     J Am Coll Cardiol. 2024;83:904-914.
     PubMed     Abstract available
     
     
     
168. MADDOX TM, Januzzi JL Jr, Allen LA, Breathett K, et al
     2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
     J Am Coll Cardiol. 2024 Mar 2:S0735-1097(23)08354.
     PubMed    
     
     
     February 2024
169. BOTTINOR W, Im C, Doody DR, Armenian SH, et al
     Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer.
     J Am Coll Cardiol. 2024;83:827-838.
     PubMed     Abstract available
     
     
     
170. BARIANI R, Rigato I, Celeghin R, Marinas MB, et al
     Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies.
     J Am Coll Cardiol. 2024;83:797-807.
     PubMed     Abstract available
     
     
     
171. YOO JE, Kim M, Kim B, Lee H, et al
     Increased Risk of Myocardial Infarction, Heart Failure, and Atrial Fibrillation After Spinal Cord Injury.
     J Am Coll Cardiol. 2024;83:741-751.
     PubMed     Abstract available
     
     
     
172. FUDIM M, Butler J, Kittipibul V
     Implantable Hemodynamic-GUIDE Monitors: A CHAMPION Among Devices for Heart Failure.
     J Am Coll Cardiol. 2024;83:695-698.
     PubMed    
     
     
     
173. LINDENFELD J, Costanzo MR, Zile MR, Ducharme A, et al
     Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.
     J Am Coll Cardiol. 2024;83:682-694.
     PubMed     Abstract available
     
     
     
174. SCHUMACHER KR, Vitale C
     It Is Shocking How Little We Have Talked About Cardiogenic Shock in Pediatrics.
     J Am Coll Cardiol. 2024;83:609-610.
     PubMed    
     
     
     
175. PURI K, Jentzer JC, Spinner JA, Hope KD, et al
     Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children.
     J Am Coll Cardiol. 2024;83:595-608.
     PubMed     Abstract available
     
     
     January 2024
176. CHHATRIWALLA AK, Cohen DJ, Vemulapalli S, Vekstein A, et al
     Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients With Functional Mitral Regurgitation.
     J Am Coll Cardiol. 2024;83:488-499.
     PubMed     Abstract available
     
     
     
177. TROLLE LAGERROS Y, Grotta A, Freyland S, Grannas D, et al
     Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors.
     J Am Coll Cardiol. 2024;83:417-426.
     PubMed     Abstract available
     
     
     
178. PACKER M
     Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2024;83:371-381.
     PubMed     Abstract available
     
     
     
179. ALOGNA A, Berboth L, Faragli A, Otvos J, et al
     Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure.
     J Am Coll Cardiol. 2024;83:47-59.
     PubMed     Abstract available
     
     
     December 2023
180. LAMBERT G, Chemello K, Gallo A
     Lipoprotein(a): More Than Just a Biomarker of Myocardial Fibrosis.
     J Am Coll Cardiol. 2023;82:2292-2295.
     PubMed    
     
     
     November 2023
181. VADUGANATHAN M, Ostrominski JW
     Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide.
     J Am Coll Cardiol. 2023;82:2097-2100.
     PubMed    
     
     
     
182. BUTLER J, Abildstrom SZ, Borlaug BA, Davies MJ, et al
     Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
     J Am Coll Cardiol. 2023;82:2087-2096.
     PubMed     Abstract available
     
     
     
183. LOWERY MM, Hill NS, Wang L, Rosenzweig EB, et al
     Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension.
     J Am Coll Cardiol. 2023;82:1989-2005.
     PubMed     Abstract available
     
     
     
184. BURGER PM, Visseren FLJ, Dorresteijn JAN
     Reply: C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank.
     J Am Coll Cardiol. 2023;82:e193.
     PubMed    
     
     
     
185. MORZE J, Rynkiewicz A
     C-Reactive Protein and Heart Failure in Patients With Established Cardiovascular Disease: Evidence From UK Biobank.
     J Am Coll Cardiol. 2023;82:e191-e192.
     PubMed    
     
     
     
186. LAU ES, Di Achille P, Kopparapu K, Andrews CT, et al
     Deep Learning-Enabled Assessment of Left Heart Structure and Function Predicts Cardiovascular Outcomes.
     J Am Coll Cardiol. 2023;82:1936-1948.
     PubMed     Abstract available
     
     
     
187. OUWERKERK W, Belo Pereira JP, Maasland T, Emmens JE, et al
     Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure.
     J Am Coll Cardiol. 2023;82:1921-1931.
     PubMed     Abstract available
     
     
     
188. COCA SG
     SGLT2i and Deterioration of Kidney Function in Heart Failure: Another Demonstration for Tolerance of "Hypercreatininemia".
     J Am Coll Cardiol. 2023;82:1864-1867.
     PubMed    
     
     
     
189. AGGARWAL R, Bhatt DL, Szarek M, Cannon CP, et al
     Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
     J Am Coll Cardiol. 2023;82:1842-1851.
     PubMed     Abstract available
     
     
     October 2023
190. REIL JC, Eitel I, Stiermaier T
     Reply: Similarities to Pacing-Induced Heart Failure.
     J Am Coll Cardiol. 2023;82:e145.
     PubMed    
     
     
     
191. KOMAMURA K
     Similarities to Pacing-Induced Heart Failure.
     J Am Coll Cardiol. 2023;82:e143.
     PubMed    
     
     
     
192. HONG KN, Eshraghian EA, Arad M, Argiro A, et al
     International Consensus on Differential Diagnosis and Management of Patients With Danon Disease: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2023;82:1628-1647.
     PubMed     Abstract available
     
     
     
193. ARNOLD SV, Goates S, Sorajja P, Adams DH, et al
     Health Status after Transcatheter Tricuspid-Valve Repair in Patients with Severe Tricuspid Regurgitation: Results from the TRILUMINATE Pivotal Trial.
     J Am Coll Cardiol. 2023 Oct 16:S0735-1097(23)07743.
     PubMed     Abstract available
     
     
     
194. OHSHIRO Y
     Empagliflozin in Patients With Heart Failure: Efficacy and Safety Concerns Across Kidney Risk Categories.
     J Am Coll Cardiol. 2023;82:e133.
     PubMed    
     
     
     
195. TEDFORD RJ, Leacche M, Lorts A, Drakos SG, et al
     Durable Mechanical Circulatory Support: JACC Scientific Statement.
     J Am Coll Cardiol. 2023;82:1464-1481.
     PubMed     Abstract available
     
     
     
196. GREGSON J, Stone GW, Bhatt DL, Packer M, et al
     Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review.
     J Am Coll Cardiol. 2023;82:1445-1463.
     PubMed     Abstract available
     
     
     September 2023
197. VERBRUGGE FH, Martens P, Mullens W
     Reply: Acetazolamide in Acute Decompensated Heart Failure.
     J Am Coll Cardiol. 2023;82:e113.
     PubMed    
     
     
     
198. PAI RG
     Acetazolamide in Acute Decompensated Heart Failure.
     J Am Coll Cardiol. 2023;82:e111.
     PubMed    
     
     
     
199. GOEL K, Lindenfeld J, Makkar R, Naik H, et al
     Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study.
     J Am Coll Cardiol. 2023;82:1281-1297.
     PubMed     Abstract available
     
     
     August 2023
200. NAYAK A, Hall SA, Uriel N, Goldstein DJ, et al
     Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device.
     J Am Coll Cardiol. 2023;82:771-781.
     PubMed     Abstract available
     
     
     
201. CHATUR S, Vaduganathan M, Claggett BL, Mc Causland FR, et al
     Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to <25ml/min/1.73m(2).
     J Am Coll Cardiol. 2023 Aug 23:S0735-1097(23)06532.
     PubMed     Abstract available
     
     
     
202. CHRISPIN J, Merchant FM, Lakdawala NK, Wu KC, et al
     Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2023;82:735-747.
     PubMed     Abstract available
     
     
     
203. GREENE SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, et al
     Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.
     J Am Coll Cardiol. 2023;82:559-571.
     PubMed     Abstract available
     
     
     
204. JALLOH MB, Averbuch T, Kulkarni P, Granger CB, et al
     Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3.
     J Am Coll Cardiol. 2023;82:544-558.
     PubMed     Abstract available
     
     
     
205. PATOLIA H, Khan MS, Fonarow GC, Butler J, et al
     Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3.
     J Am Coll Cardiol. 2023;82:529-543.
     PubMed     Abstract available
     
     
     
206. GRAPSA J, Pinney SP
     Right Heart Dysfunction in HFpEF: More Complex and More Common Than We Thought.
     J Am Coll Cardiol. 2023;82:500-502.
     PubMed    
     
     
     
207. BUTLER J, Khan MS, Fonarow GC
     The Need for Global Optimization of Heart Failure Therapy: Some Differences Do Not Matter.
     J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05963.
     PubMed    
     
     
     
208. KONDO T, Wang X, Yang M, Jhund PS, et al
     Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
     J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05964.
     PubMed     Abstract available
     
     
     
209. SROUBEK J, Vajapey R, Sipko JJ, Soltesz EG, et al
     First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation.
     J Am Coll Cardiol. 2023;82:469-471.
     PubMed    
     
     
     
210. DEVORE AD, Allen LA
     A Global Challenge and a Global Opportunity for the Heart Failure Community.
     J Am Coll Cardiol. 2023;82:445-447.
     PubMed    
     
     
     
211. FOROUTAN F, Rayner DG, Ross HJ, Ehler T, et al
     Global Comparison of Readmission Rates for Patients With Heart Failure.
     J Am Coll Cardiol. 2023;82:430-444.
     PubMed     Abstract available
     
     
     
212. JIALAL I, Ebong IA
     The Evolving Role of C-Reactive Protein in Heart Failure: Implications for Patients With Cardiovascular Disease.
     J Am Coll Cardiol. 2023;82:427-429.
     PubMed    
     
     
     
213. BURGER PM, Koudstaal S, Mosterd A, Fiolet ATL, et al
     C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease.
     J Am Coll Cardiol. 2023;82:414-426.
     PubMed     Abstract available
     
     
     
214. SAUER AJ, Hsia J
     Initiating Mineralocorticoid Antagonists for Longstanding Heart Failure With Reduced Ejection Fraction: Better Late Than Never?
     J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06074.
     PubMed    
     
     
     
215. MATSUMOTO S, Kondo T, Jhund PS, Campbell RT, et al
     Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
     J Am Coll Cardiol. 2023 Aug 1:S0735-1097(23)06073.
     PubMed     Abstract available
     
     
     July 2023
216. VIJAYARAMAN P, Sharma PS, Cano O, Ponnusamy SS, et al
     Comparison of Left Bundle Branch Area Pacing and Biventricular Pacing in Candidates for Resynchronization Therapy.
     J Am Coll Cardiol. 2023;82:228-241.
     PubMed     Abstract available
     
     
     
217. DOCHERTY KF, McDowell K, Welsh P, Osmanska J, et al
     Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.
     J Am Coll Cardiol. 2023;82:142-157.
     PubMed     Abstract available
     
     
     
218. ANKER MS, von Haehling S, Landmesser U
     Understanding Who Responds to M-TEER in Heart Failure With SMR: Malnutrition Does Not Preclude Benefit.
     J Am Coll Cardiol. 2023;82:139-141.
     PubMed    
     
     
     
219. BAYES-GENIS A, de la Espriella R, Nunez J
     CA125 for Fluid Overload Monitoring: A New Life for an Old Tool.
     J Am Coll Cardiol. 2023;82:158-160.
     PubMed    
     
     
     
220. GRINSTEIN J, Belkin MN, Kalantari S, Bourque K, et al
     Adverse Hemodynamic Consequences of Continuous Left Ventricular Mechanical Support: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2023;82:70-81.
     PubMed     Abstract available
     
     
     June 2023
221. WIVIOTT SD, Berg DD
     SGLT2 Inhibitors Reduce Heart Failure Hospitalization and Cardiovascular Death: Clarity and Consistency.
     J Am Coll Cardiol. 2023;81:2388-2390.
     PubMed    
     
     
     
222. USMAN MS, Siddiqi TJ, Anker SD, Bakris GL, et al
     Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
     J Am Coll Cardiol. 2023;81:2377-2387.
     PubMed     Abstract available
     
     
     
223. GODOY LC, Farkouh ME, Austin PC, Shah BR, et al
     Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease.
     J Am Coll Cardiol. 2023;81:2299-2311.
     PubMed     Abstract available
     
     
     
224. STEVENSON LW, Ross HJ, Rathman LD, Boehmer JP, et al
     Remote Monitoring for Heart Failure Management at Home.
     J Am Coll Cardiol. 2023;81:2272-2291.
     PubMed     Abstract available
     
     
     
225. GOLDBERG LR
     Disrupting the Definition of Heart Failure: A Rose by Any Other Name.
     J Am Coll Cardiol. 2023;81:2243-2245.
     PubMed    
     
     
     
226. MOHEBI R, Wang D, Lau ES, Parekh JK, et al
     Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort.
     J Am Coll Cardiol. 2023;81:2231-2242.
     PubMed     Abstract available
     
     
     
227. LEWIS MJ, Reardon LC, Aboulhosn J, Haeffele C, et al
     Morbidity and Mortality in Adult Fontan Patients After Heart or Combined Heart-Liver Transplantation.
     J Am Coll Cardiol. 2023;81:2161-2171.
     PubMed     Abstract available
     
     
     
228. FONAROW GC, Greene SJ
     Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: Strong Impact Across Ejection Fraction Spectrum.
     J Am Coll Cardiol. 2023;81:2145-2148.
     PubMed    
     
     
     
229. PAGNESI M, Metra M, Cohen-Solal A, Edwards C, et al
     Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.
     J Am Coll Cardiol. 2023;81:2131-2144.
     PubMed     Abstract available
     
     
     May 2023
230. KAZI DS, DeJong C, Chen R, Wadhera RK, et al
     The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
     J Am Coll Cardiol. 2023;81:2103-2111.
     PubMed     Abstract available
     
     
     
231. SCOTTI A, Coisne A, Granada JF, Driggin E, et al
     Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.
     J Am Coll Cardiol. 2023 May 27:S0735-1097(23)05584.
     PubMed     Abstract available
     
     
     
232. SUKUMAR S, Wasfy JH, Januzzi JL, Peppercorn J, et al
     Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2023;81:2043-2055.
     PubMed     Abstract available
     
     
     
233. VERBRUGGE FH, Martens P, Dauw J, Nijst P, et al
     Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload.
     J Am Coll Cardiol. 2023;81:2013-2024.
     PubMed     Abstract available
     
     
     
234. JOYCE E
     Natriuretic Response as a Biomarker of Decongestion in ADHF: Beyond Going With the Flow.
     J Am Coll Cardiol. 2023;81:2025-2027.
     PubMed    
     
     
     
235. KRISTENSEN SL, Jensen J, Schou M
     SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
     J Am Coll Cardiol. 2023;81:1915-1917.
     PubMed    
     
     
     
236. BUTLER J, Packer M, Siddiqi TJ, Bohm M, et al
     Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
     J Am Coll Cardiol. 2023;81:1902-1914.
     PubMed     Abstract available
     
     
     
237. INCIARDI RM, Abanda M, Shah A, Cikes M, et al
     Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial.
     J Am Coll Cardiol. 2023 May 15:S0735-1097(23)05587.
     PubMed     Abstract available
     
     
     
238. MENTZ RJ, Ward JH, Hernandez AF, Lepage S, et al
     Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
     J Am Coll Cardiol. 2023 May 11:S0735-1097(23)05429.
     PubMed     Abstract available
     
     
     
239. KITTLESON MM, Panjrath GS, Amancherla K, Davis LL, et al
     2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
     J Am Coll Cardiol. 2023;81:1835-1878.
     PubMed    
     
     
     
240. BORLAUG BA, Sharma K, Shah SJ, Ho JE, et al
     Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement.
     J Am Coll Cardiol. 2023;81:1810-1834.
     PubMed     Abstract available
     
     
     
241. KODALI SK, Hahn RT, Davidson CJ, Narang A, et al
     1-Year Outcomes of Transcatheter Tricuspid Valve Repair.
     J Am Coll Cardiol. 2023;81:1766-1776.
     PubMed     Abstract available
     
     
     
242. VENTURA HO, Lavie CJ, Mehra MR
     Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction: You Win Some, You Lose Some.
     J Am Coll Cardiol. 2023 May 3:S0735-1097(23)05526.
     PubMed    
     
     
     
243. MAMIC P, Snyder M, Tang WHW
     Gut Microbiome-Based Management of Patients With Heart Failure: JACC Review Topic of the Week.
     J Am Coll Cardiol. 2023;81:1729-1739.
     PubMed     Abstract available
     
     
     
244. FONAROW GC, Van Spall HGC, Januzzi JL Jr
     Team-Based Virtual Nudges to Overcome Clinician Inertia in Guideline-Directed Medical Therapy for Heart Failure.
     J Am Coll Cardiol. 2023;81:1694-1696.
     PubMed    
     
     
     April 2023
245. MIRANDA WR, Jain CC, Borlaug BA, Jaffe AS, et al
     Exercise Capacity, NT-proBNP, and Exercise Hemodynamics in Adults Post-Fontan.
     J Am Coll Cardiol. 2023;81:1590-1600.
     PubMed     Abstract available
     
     
     
246. LENA A, Wilkenshoff U, Hadzibegovic S, Porthun J, et al
     Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer.
     J Am Coll Cardiol. 2023;81:1569-1586.
     PubMed     Abstract available
     
     
     
247. VERMA S, Bhatt DL, Dhingra NK, Steg PG, et al
     Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
     J Am Coll Cardiol. 2023;81:1546-1549.
     PubMed    
     
     
     
248. KHAN H, Kunutsor SK
     Nonsteroidal Anti-Inflammatory Drugs and Type 2 Diabetes: A Recipe for Heart Failure?
     J Am Coll Cardiol. 2023;81:1471-1473.
     PubMed    
     
     
     
249. HOLT A, Strange JE, Nouhravesh N, Nielsen SK, et al
     Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus.
     J Am Coll Cardiol. 2023;81:1459-1470.
     PubMed     Abstract available
     
     
     
250. COCA SG
     Learning to Embrace the Decline in eGFR After Initiation of Therapies for Heart Failure.
     J Am Coll Cardiol. 2023;81:1456-1458.
     PubMed    
     
     
     
251. AHMAD T, Desai NR, Clark KAA
     The EHR Has Exposed an Urgent Moral Imperative to Improve Heart Failure Care.
     J Am Coll Cardiol. 2023;81:1317-1319.
     PubMed    
     
     
     
252. YUN M, Bai Y, Nie B, Zhang X, et al
     Reply: Specific Brain-Heart Axis-Related Pathomechanism in Heart Failure Are Revealed Through Analysis of Cardiovascular Dynamics.
     J Am Coll Cardiol. 2023;81:e111.
     PubMed    
     
     
     
253. VALENZA G
     Specific Brain-Heart Axis-Related Pathomechanism in Heart Failure Are Revealed Through Analysis of Cardiovascular Dynamics.
     J Am Coll Cardiol. 2023;81:e109.
     PubMed    
     
     
     
254. CARNICELLI AP, Agarwal R, Tedford RJ, Ramaiah V, et al
     Critical Care Enrichment During Advanced Heart Failure Training.
     J Am Coll Cardiol. 2023;81:1296-1299.
     PubMed    
     
     
     
255. SORAJJA P, Cavalcante JL, Rodes-Cabau J
     Upstream Relief of Heart Failure Via Aortic Valve Replacement.
     J Am Coll Cardiol. 2023;81:1245-1247.
     PubMed    
     
     
     
256. KHAN KR, Khan OA, Chen C, Liu Y, et al
     Impact of Moderate Aortic Stenosis in Patients With Heart Failure With Reduced Ejection Fraction.
     J Am Coll Cardiol. 2023;81:1235-1244.
     PubMed     Abstract available
     
     
     March 2023
257. DOMANSKI MJ, Wu CO, Tian X, Hasan AA, et al
     Association of Incident Cardiovascular Disease With Time Course and Cumulative Exposure to Multiple Risk Factors.
     J Am Coll Cardiol. 2023;81:1151-1161.
     PubMed     Abstract available
     
     
     
258. LYNCH A, Tatangelo M, Ahuja S, Steve Fan CP, et al
     Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy.
     J Am Coll Cardiol. 2023;81:1035-1045.
     PubMed     Abstract available
     
     
     
259. DISMORR M, Glaser N, Franco-Cereceda A, Sartipy U, et al
     Effect of Prosthesis-Patient Mismatch on Long-Term Clinical Outcomes After Bioprosthetic Aortic Valve Replacement.
     J Am Coll Cardiol. 2023;81:964-975.
     PubMed     Abstract available
     
     
     
260. VADUGANATHAN M, Claggett BL, Jhund P, Miao ZM, et al
     Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction.
     J Am Coll Cardiol. 2023;81:1004-1006.
     PubMed    
     
     
     
261. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
     Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
     J Am Coll Cardiol. 2023 Mar 14:S0735-1097(23)00368.
     PubMed     Abstract available
     
     
     
262. LAZARO I, Lupon J, Cediel G, Sala-Vila A, et al
     Reply: Circulating Vegetable Omega-3 and Prognosis in Patients With Heart Failure: More Data Are Needed.
     J Am Coll Cardiol. 2023;81:e69.
     PubMed    
     
     
     
263. WU J, Liang J, Huang Y
     Circulating Vegetable Omega-3 and Prognosis in Patients With Heart Failure: More Data Are Needed.
     J Am Coll Cardiol. 2023;81:e67.
     PubMed    
     
     
     
264. MENASCHE P
     Mesenchymal Stromal Cell Therapy for Heart Failure: Never Stop DREAMing.
     J Am Coll Cardiol. 2023;81:864-866.
     PubMed    
     
     
     
265. PERIN EC, Borow KM, Henry TD, Mendelsohn FO, et al
     Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.
     J Am Coll Cardiol. 2023;81:849-863.
     PubMed     Abstract available
     
     
     February 2023
266. BHATT AS, Varshney AS, Moscone A, Claggett BL, et al
     Virtual Care Team-Guided Therapeutic Optimization During Hospitalization in Patients with Heart Failure: The IMPLEMENT-HF Study.
     J Am Coll Cardiol. 2023 Feb 21:S0735-1097(23)04471.
     PubMed     Abstract available
     
     
     
267. MUKHOPADHYAY A, Reynolds HR, Phillips LM, Nagler AR, et al
     Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care.
     J Am Coll Cardiol. 2023 Feb 9:S0735-1097(23)00329.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.